ACHILLES THERAP.SP.ADS/1
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the t… Read more
ACHILLES THERAP.SP.ADS/1 (698) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ACHILLES THERAP.SP.ADS/1 (698) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ACHILLES THERAP.SP.ADS/1 - Net Assets Trend (None–None)
This chart illustrates how ACHILLES THERAP.SP.ADS/1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACHILLES THERAP.SP.ADS/1 (None–None)
The table below shows the annual net assets of ACHILLES THERAP.SP.ADS/1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ACHILLES THERAP.SP.ADS/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ACHILLES THERAP.SP.ADS/1 Competitors by Market Cap
The table below lists competitors of ACHILLES THERAP.SP.ADS/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Children’s Place Inc
NASDAQ:PLCE
|
$28.47 Million |
|
Island Pharmaceuticals Ltd
AU:ILA
|
$28.48 Million |
|
Imugene Ltd
AU:IMU
|
$28.49 Million |
|
NicOx S.A.
PA:ALCOX
|
$28.49 Million |
|
Quantum-Si incorporated
NASDAQ:QSIAW
|
$28.46 Million |
|
Broncus Holding Corporation
PINK:BRNHF
|
$28.45 Million |
|
Soonest Express Co Ltd
TWO:2643
|
$28.44 Million |
|
TIL Limited
NSE:TIL
|
$28.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACHILLES THERAP.SP.ADS/1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ACHILLES THERAP.SP.ADS/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ACHILLES THERAP.SP.ADS/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ACHILLES THERAP.SP.ADS/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACHILLES THERAP.SP.ADS/1 (698) | €- | N/A | N/A | $28.46 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |